Overview

The NGS 10 gene lung cancer risk panel screens ten high-impact targeted genes to flag individuals at elevated inherited or early lung cancer risk. This article describes the populations for whom a focused ten-gene screen is most appropriate, offered by GIVE LIFE TIME International. A compact panel lowers the barrier to routine risk screening.

How It Works

A simple nucleic-acid sample is prepared into a targeted library covering ten recurrently altered lung genes and sequenced on a compact next-generation platform. The concise design keeps cost and turnaround low while capturing the most decision-relevant drivers. Automated analysis returns a clear positive or negative call per gene.

Indications

It fits screening of high-risk smokers, families with clustered lung cancer, and patients needing a quick driver check before therapy. The small panel is ideal where a one-hundred-plus gene workup is unnecessary. It is also a sensible entry test before committing to broader profiling.

Specimen & Processing

A peripheral blood or saliva sample is collected using the standard kit, with no biopsy required. DNA is extracted and prepared into the targeted ten-gene library at the laboratory. Kits include stabilizers that protect the sample in transit. Sample identity is confirmed at every handoff, and residual material from the population-focused workflow is retained for optional confirmatory re-analysis.

Storage & Sourcing

Reports are delivered as a secure PDF within four to six working days, with counseling guidance attached. GIVE LIFE TIME International supplies collection kits and supports screening programs with batch logistics and reminder workflows for repeat testing. Client portals return multi-language reports for the NGS program and support bulk export to hospital information systems.

FAQ

Q: Who should consider the 10 gene lung risk panel? A: Long-term smokers, people with a family cluster of lung cancer, and patients needing a fast driver check are the best candidates. Clinicians may also use it for pre-therapy triage.

Q: How does it differ from a large NGS panel? A: It covers only the ten most actionable lung genes, so it is faster and cheaper while still catching the common drivers. Larger panels add breadth that many screening cases do not need.

Q: What sample is required for the test? A: A peripheral blood or saliva sample is enough, which makes broad screening far easier to collect than tissue. Self-collection kits simplify outreach programs.

Q: How are positive findings followed up? A: A positive result triggers imaging or a larger confirmatory panel and referral according to the local care pathway. Genetic counseling is recommended for inherited findings.